BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2单克隆抗体与小鼠PD-L1(也称为B7-H1或CD274)反应。PD-L1是属于Ig超家族的B7家族的I型跨膜蛋白,分子量为40kDa。PD-L1在T淋巴细胞、B淋巴细胞、NK细胞、树突状细胞以及IFNγ刺激的单核细胞、上皮细胞和内皮细胞上表达。PD-L1与CD4和CD8胸腺细胞以及...
BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2抗体已被证明可以阻断PD-L1和PD-1之间以及PD-L1和B7-1之间的相互作用(CD80)。 欣博盛生物是Bioxcell国内授权代理商,Bioxcell现货库存中心,如需购买BE0101或Bioxcell其它产品,请联系! BioXcell BE0101 产品详情: 产品名称 InVivoMAb anti-mouse PD-L1...
Immunofluorescence) 1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840. 更多产品详情请咨询 BioXCell 中国授权代理——欣博盛生物 ...
BioXcell InVivoMab anti-mouse PD-L1 (B7-H1) 10F.9G2抗体已被证明可以阻断PD-L1和PD-1之间以及PD-L1和B7-1之间的相互作用(CD80)。 欣博盛生物是BioXcell 授权国内代理商,如需购买BioXcell Be0101产品或Bioxcell其它产品,技术问题,请联系我们。 BioXcell BE0101 Specifications/产品详情 部分相关文献: in ...
上海玉博生物科技有限公司 主要致力于“Anti-B7-H1/PDL1/CD274(programmed death ligand 1) 程序性死亡配体1抗体 yb-1103R”的生产销售。多年的“Anti-B7-H1/PDL1/CD274(programmed death ligand 1) 程序性死亡配体1抗体 yb-1103R”生产与销售的经验,与各行业新老用户建
Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response ArticleOpen access18 June 2023 Introduction The novel antibody-based immunotherapy in oncology exploits the activation of immune system, such as the stimulation of T-cells against cancer, mediated by...
(B) Flow cytometry for cell surface PDL1 in Rab27a knockout and Rab27a ;Pd-l1 double knockout MC38 cells. For double knockouts, Pd-l1 was mutated in a background of Rab27a null cells. (C) Representative H&E for each category of lymphocyte infiltration show in Figure 6E. (D–G)...
AntiPD-1 antibody was injected (i.p.) (10 mg/kg twice weekly) [25]. CD8+ T cells were depleted in a subset of mice by intraperitoneal injection of CD8a depletion antibody (BioXcell, 2.43 clone), 3 times per week at 150 μg per animal. Drugs were given for the duration of ...
Three randomised cohorts (n = 5) with tumour size between 30 and 50 mm3 were administered vehicle control (DMSO, i.p., QD) or anti-PD-1 (BioXcell, BE0146, Clone: RMP1–14, RRID:AB_10949053) (10 mg·kg−1, i.p., BIW) or ZE132 (40 mg·kg−1, i.p., QD). ...
three times a week, starting 1 day after cancer cell inoculation, with anti-PDL1 mAb (200 μg/mouse; clone 10 F.9G2, BioXcell), anti-CTLA4 mAb (200 μg/mouse; clone 9D9, BioXcell), anti-PD1 mAb (200 μg/mouse; clone RMP1-14, BioXcell), alone or in combinations ...